GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,401.00GBp
5 Feb 2016
Change (% chg)

-11.50p (-0.81%)
Prev Close
1,412.50p
Open
1,409.00p
Day's High
1,422.00p
Day's Low
1,398.50p
Volume
9,903,664
Avg. Vol
7,905,870
52-wk High
1,645.00p
52-wk Low
1,227.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic... (more)

Overall

Beta: 0.70
Market Cap(Mil.): £68,229.96
Shares Outstanding(Mil.): 4,870.09
Dividend: 23.00
Yield (%): 5.71

Financials

  GSK.L Industry Sector
P/E (TTM): 8.03 31.76 38.72
EPS (TTM): 1.75 -- --
ROI: 26.60 15.12 14.47
ROE: 179.63 15.85 15.40
Search Stocks

GSK refuses to be bounced into early consumer unit spin-off

LONDON GlaxoSmithKline said on Wednesday it would not be pushed into an early spin-off or sale of its consumer health business, despite speculation the unit could be a target for the likes of Reckitt Benckiser or Procter & Gamble . | Video

03 Feb 2016

GSK dismisses near-term split as new drugs offset falling Advair

LONDON GlaxoSmithKline said on Wednesday the chance of it spinning off or selling its consumer health business before 2018 was "extraordinarily low", arguing the group's strategy was delivering, helped by rising sales of new medicines.

03 Feb 2016

UPDATE 3-GSK dismisses near-term split as new drugs offset falling Advair

* Q4 sales 6.29 bln stg vs consensus 6.25 bln (Adds more on options for consumer health business)

03 Feb 2016

GSK refuses to be bounced into early consumer unit spin-off

LONDON, Feb 3 GlaxoSmithKline said on Wednesday it would not be pushed into an early spin-off or sale of its consumer health business, despite speculation the unit could be a target for the likes of Reckitt Benckiser or Procter & Gamble.

03 Feb 2016

RPT-New drugs help GSK offset drag of flagging Advair sales

LONDON, Feb 3 Growing demand for new drugs helped GlaxoSmithKline beat forecasts for fourth-quarter earnings by a small margin on Wednesday, offsetting a continued slide in sales of its older Advair respiratory medicine.

03 Feb 2016

BRIEF-GlaxoSmithKline says latest estimate for R&D rate of return of 13 pct

* Have also published our latest estimate for the rate of return in research and development, which has been maintained at 13 pct

03 Feb 2016

BRIEF-GSK Q4 core EPS beats estimate

* Q4 revenue 6,286 million stg (thomson reuters consensus 6,256 million stg)

03 Feb 2016

BRIEF-GSK says seeking U.S. approval for expanded indication for influenza vaccine

* Announces U.S. regulatory submission seeking expanded indication for flulaval quadrivalent (influenza vaccine) for infants 6 mos+

02 Feb 2016

GSK and J&J back $1 billion biotech spin-off from Index Ventures

LONDON Index Ventures, an early investor in technology hits like Skype and Dropbox, is spinning off its biotech portfolio into a new $1 billion (695 million pounds) business, with backing from drug giants GlaxoSmithKline and Johnson & Johnson .

02 Feb 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks